Meeting the challenge of antibiotic resistance

BMJ

Volumn 337, Issue 7672, 2008, Pages 726-728

  Cars, Otto ^a   Högberg, Liselotte Diaz ^a   Murray, Mary ^c   Nordberg, Olle ^b   Sivaraman, Satya ^c   Lundborg, Cecilia Stålsby ^d,e   So, Anthony D ^f   Tomson, Göran ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b Dag Hammarskjold Foundation   (Sweden)

^c Karolinska Institutet ^*

^d KAROLINSKA INSTITUTE   (Sweden)

^e NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^f DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; BEHAVIOR CHANGE; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; HEALTH CARE; HEALTH CARE SYSTEM; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 53049109052     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (38)

1. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-acquired neonatal infections in developing countries. Lancet 2005;365:1175-88.
2. Blomberg B, Manji KP, Urassa WK, Tamim BS, Mwakagile DS, Jureen R, et al. Antimicrobial resistance predicts death in Tanzanian children with bloodstream infections: a prospective cohort study. BMC Infect Dis 2007;7:43.
3. National Statistics. MRSA deaths decrease in 2007www.statistics. gov.uk/cci/nugget.asp?id=1067
4. European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe. December 2007. http://ecdc.europa.eu/pdf/ECDC_epi_report_2007.pdf
5. ReAct - Action on Antibiotic Resistance. Burden of resistance to multi-resistant gram-negative bacilli (MRGN). 1 March 2007. http://soapimg.icecube.snowfall.se/stopresistance/ ReAct_Burden%20of%20resistance%20to%20Multi%20resist%20and%20Gram%20 negative%20Bacilli%20MRGN.pdf
6. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006;368:874-85.
7. World Health Organization. Report on infectious diseases 2000: overcoming antimicrobial resistance. 2000. www.who.int/infectious-disease- report/2000/index.html
8. Cantón R, Coque TM. The CTX-M β-lactamase pandemic. Current Opinion in Microbiology 2006;9:466-75.
9. World Health Organization. World health report 2007: a safer future: global public health security in the 21st century. 2007. www.who.int/whr/2007/whr07_en.pdf
10. Butaye P, Michael G B, Schwarz S, Barrett TJ, Brisabois A, White DG. The clonal spread of multidrug-resistant non-typhi Salmonella serotypes. Microb Infect 2006;8:1891-7.
11. Huovinen P, Cars O. Control of antimicrobial resistance: time for action. BMJ 1998;317:613-4.
12. Hawkey PM. Action against antibiotic resistance: no time to lose. Lancet 1998;351:1298-9.
13. World Health Assembly. Emerging and other communicable diseases: antimicrobial resistance. May 1998. http://mednet3.who.int/prioritymeds/ report/append/microb_wha5117.pdf
14. World Health Organization. Global strategy for containmentof antimicrobial resistance. 2001. www.who.int/drugresistance/ WHO_Global_Strategy_English.pdf
15. World Health Assembly. Improving the containment of antimicrobial resistance. May 2005. www.tufts.edu/med/apua/Chapters/WHA58_27-en.pdf
16. Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA. Growing problem of multidrug-resistant enteric pathogens in Africa. Emerg Infect Dis 2007;13(11). www.cdc.gov/EID/content/13/11/1640.htm
17. Grigoryan L, Haaijer-Ruskamp FM, Johannes Burgerhof GM, Mechtler R, Deschepper R, Tambic-Andrasevic A, et al. Self-medication with antibiotics in the general population: a survey in nineteen European countries. Emerg Infect Dis 2006;12(3). www.cdc.gov/ncidod/EID/vol12no03/05-0992.htm
18. Carbon C, Cars O, Christiansen K. Moving from recommendation to implementation and audit: part 1. Current recommendations and programs: a critical commentary. Clin Microbiol Infect 2002;8(suppl 2):92-106.
19. Mölstad S, Erntell M, Hanberger H, Melander E, Norman C, Skoog G, et al. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis 2008;8:125-32.
20. Bavestrello FL, Cabello MA, Casanova Z, Dunny. Impact of regulatory measures on antibiotic sales in Chile. Rev Méd Chile 2002;130:1265-72.
21. Harbarth S, Samore MH. Antimicrobial resistance determinants and future control. Emerg Infect Dis 2005;11(6). www.cdc.gov/ncidod/EID/vol11no06/ 05-0167.htm
22. Chen C, Chen YM, Hwang KL, Lin SJ, Yang CC, Tsay RW, et al. Behavior, attitudes, and knowledge about antibiotic usage among residents of Changhua, Taiwan. J Microbiol Immunol Infect 2005;38:53-9.
23. Trepka M, Belongia E, Chyou P-H, Davis J, Schwartz B. The effect of a community intervention trial on parental knowledge and awareness of antibiotic resistance and appropriate antibiotic use in children. Pediatrics 2001;107:6.
24. Macfarlane J, Holmes W, Macfarlane R, Britten N. Influence of patients' expectations on antibiotic management of acute lower respiratory tract illness in general practice: questionnaire study. BMJ 1997;315:1211-4.
25. Del Mar C. Prescribing antibiotics in primary care. BMJ 2007;335:407-8.
26. Sjölund M, Wreiber K, Andersson DI, Blaser MI, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 2003 16;139:483-7.
27. Nasrin D, Collignon PJ, Roberts L, Wilson EJ, Pilotto LS, Douglas RM. Effect of beta lactam antibiotic use in children on pneumococcal resistance to penicillin: prospective cohort study. BMJ 2002;324:28-30.
28. Dollman WB, LeBlanc VT, Stevens L, O'Connor PJ, Turnidge JD. A community-based intervention to reduce antibiotic use for upper respiratory tract infections in regional South Australia. Med J Aust 2005;182:617-20.
29. Awad AI, Eltayeb IB, Baraka OZ. Changing antibiotics prescribing practices in health centers of Khartoum State, Sudan. Eur J Clin Pharmacol 2006;62:135-42.
30. Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnate and a public health crisis brews. July 2004. www.idsociety.org/badbugsnodrugs.html
31. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004;38:1279-86.
32. Projan SJ. Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003;6:427-30.
33. Outterson K, Samora JB, Keller-Cuda K. Will longer antimicrobial patents improve global public health? Lancet Infect Dis 2007;7:559-66.
34. Payne D, Tomasz A. The challenge of antibiotic resistant bacterial pathogens: the medical need, the market, and prospects for new antimicrobial agents. Curr Opin Microbiol 2004;7:435-8.
35. Cars O, So A, Högberg L, Manz C. Innovating for bacterial resistance. ESCMID News 2007;2:22-4.
36. Moran M. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med 2005;2:e302.
37. Document prepared by the World Band and GAVI under the guidance of Governments of Italy, Canada, and the United Kingdom. AMC Pilot Proposal. 7 September 2006. www.vaccineamc.org/files/AMCPilotProposal.pdf
38. Laxminarayan R, Malani A, Howard D, Smith DL. Extending the cure: policy responses to the growing threat of antibiotic resistance. Alexandria: Resources for the Future, 2007. www.extendingthecure.org/research_and_downloads.html